Latest filing published 11 Jul 2025 for EyePoint Pharmaceuticals, Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Karen L. Zaderej across 2 companies, led by Axogen, Inc. and EyePoint, Inc. Between 19 July 2021 and 18 August 2026, the trades on record add up to 21 filings.
Every open-market trade on record is a purchase: 4 purchases worth €185k, and no sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 4 share grants and 13 option exercises. So far in 2026, the count stands at 1 purchase and no sales.
A typical purchase (the median) is worth €36k. Clusters matter here: 1 out of 4 purchases overlapped with buying by a colleague within 30 days. Purchases made close together by different insiders form what is called a cluster.
The record was last updated on 18 August 2026 with an open-market purchase (€45k) in EyePoint, Inc. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
20 of 20 declarations